Clinical characteristics and etiological analysis of severe pneumonia complicated with acute respiratory failure in children before and after COVID-19

doi:10.3969/j.issn.1004-583X.2024.02.008

Abstract

Abstract:

Objective To investigate the clinical characteristics and etiological analysis of severe pneumonia complicated with acute respiratory failure (SP-ARF) in children before and after the coronavirus disease 2019 (COVID-19) outbreak in Suzhou. Methods This study retrospectively analyzed the medical records of all SP-ARF children admitted to the Children’s Hospital of Soochow University from January 2018 to December 2021, and they were divided into pre-epidemic group (January 2018 to December 2019) and post-epidemic group (January 2020 to December 2021) according to the outbreak time. The clinical data and etiological results of the two groups were analyzed. Results There were 141 cases in the pre-epidemic group and 127 cases in the post-epidemic group. The month-age of children with SP-ARF in the post-epidemic group were older than those of pre-epidemic group (P<0.05), and with a higher proportion of combined underlying diseases (P<0.05). The peak period of SP-ARF was from October to December every year regardless of before or after the epidemic. The positive rate of etiological examination in pre-epidemic group was 82.27%(116/141). The top 4 bacteria were in order of Gram-negative bacteria (36.88%), Gram-positive bacteria (26.95%), viruses (26.95%), and mycoplasma pneumoniae (9.22%). The positive rate of etiological examination in posr-epidemic group was 85.83% (109/127), and the top 4 bacteria were in order of Gram-negative bacteria (37.80%), virus (28.35%), Gram-positive bacteria (22.83%), and Mycoplasma pneumoniae (9.45%). Conclusion After the epidemic, the proportion of children without underlying diseases developing SP-ARF decreased, SP-ARF occurred frequently from October to December every year regardless of before or after the epidemic. The pathogens of the two groups were mainly bacteria, with highest proportion of Gram-negative bacteria.

Key words: pneumonia, respiratory insufficiency, COVID-19

CLC Number:

R563.1

Huang Saihu, Long Zhongjie, Wu Shuiyan, Bai Zhenjiang. Clinical characteristics and etiological analysis of severe pneumonia complicated with acute respiratory failure in children before and after COVID-19[J]. Clinical Focus, 2024, 39(2): 140-143.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.02.008

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I2/140

Figures/Tables 4

References 26

[1]	Watkins K, Sridhar D. Pneumonia:A global cause without champions[J]. Lancet, 2018, 392 (10149):718-719. doi: S0140-6736(18)31666-0 pmid: 30191817
[2]	Azoulay E, Mokart D, Kouatchet A, et al. Acute respiratory failure in immunocompromised adults[J]. Lancet Respir Med, 2018, 7 (2):173-186. doi: 10.1016/S2213-2600(18)30345-X URL
[3]	Qi GJ, Chao YL, Xi XY, et al. Effect analysis of early bedside hemofiltration in treatment of severe pneumonia with acute renal failure of children.[J]. Eur Rev Med Pharmacol, 2015, 19(24):4795-4800.
[4]	郭军. 经鼻持续气道正压通气治疗儿童重症肺炎合并呼吸衰竭的临床疗效和安全性评价[J]. 中国医疗器械信息, 2019, 25(21):126-127.
[5]	雷勋明, 谢娜, 李尚文. 早期 NCPAP 对重症肺炎并呼吸衰竭患儿血气指标及 PCIS 的影响[J]. 湖北医药学院学报, 2020, 39(4):381-383.
[6]	黄填. 小儿重症肺炎采用经鼻持续气道正压通气疗法治疗的效果观察[J]. 中国现代药物应用, 2020, 14(13):60-62.
[7]	Deluca AN, Hammitt LL, Kim J, et al. Safety of induced sputum collection in children hospitalized with severe or very severe pneumonia[J]. Clin Infect Dis, 2017, 64(suppl_3):S301-S308. doi: 10.1093/cid/cix078 URL
[8]	蒋荣猛, 谢正德, 蒋毅, 等. 儿童新型冠状病毒感染诊断、治疗和预防专家共识(第三版)[J]. 中国实用儿科临床杂志, 2021, 36(10):721-731.
[9]	花盛浩, 邵雪君, 徐俊. 新型冠状病毒肺炎常态化防控下儿童常见呼吸道病毒感染谱的变化[J]. 中华传染病杂志, 2021, 39(10):621-625.
[10]	中华医学会儿科学分会呼吸学组. 《中华儿科杂志》编辑委员会. 儿童社区获得性肺炎管理指南(2013修订)(上)[J]. 中华儿科杂志, 2013, 51(10):745-752.
[11]	Wong JJM, Jit M, Sultana R, et al. Mortality in pediatric acute respiratory distress syndrome: A systematic review and meta-analysis[J]. J Intensive Care Med, 2019, 34(7): 563-571. doi: 10.1177/0885066617705109 URL
[12]	陈强, 胡向荣. 早期持续气道正压通气在重症肺炎并发呼吸衰竭患儿中的应用[J]. 深圳中西医结合杂志, 2022, 32(15):112-114.
[13]	方杏香, 陆丹琼, 王颖, 等. CPAP辅助治疗重症肺炎合并呼吸衰竭患儿预后影响因素分析及对策[J]. 中国妇幼保健, 2021, 36(23):5522-5525.
[14]	周巍玲, 魏升云, 张孝兴. 经鼻持续气道正压通气联合丙种球蛋白治疗儿童重症肺炎并呼吸衰竭疗效的影响因素[J]. 中国妇幼健康研究, 2022,(2):76-80.
[15]	Azoulay E, Russell L, Van de Louw A, et al. Diagnosis of severe respiratory infections in immunocompromised patients[J]. Intensive Care Med, 2020, 46(2):298-314. doi: 10.1007/s00134-019-05906-5 pmid: 32034433
[16]	王丰军, 王丽敏, 雒挺保, 等. 学龄前儿童急性重症肺炎合并呼吸衰竭的急诊急救体会及感染病原学、药敏试验分析[J]. 中国妇幼保健, 2019, 34(7):1576-1578.
[17]	杨琴, 马红玲, 王卫, 等. 儿童下呼吸道流感病毒感染危重症临床特征分析[J]. 中国小儿急救医学, 2020, 27(7):502-506.
[18]	王亚翠, 吴喜蓉, 刘芳, 等. 2016年至2019年北京住院儿童肺炎支原体感染流行病学特征和耐药性[J]. 中华实用儿科临床杂志, 2022, 37(14):1082-1084.
[19]	付玉林, 董艳, 李静. 2018-2019年北京市儿童社区获得性肺炎的病原学分析及临床特点[J]. 中国医药科学, 2022, 12(8):126-129.
[20]	金必青, 顾浩翔, 吴蓓蓉, 等. 儿童社区获得性肺炎住院时间的影响因素分析[J]. 同济大学学报(医学版), 2023, 44(5):689-695.
[21]	黄艳智, 孙利伟, 刘宇奇, 等. 618例小儿重症社区获得性肺炎病原谱及临床特点分析[J]. 中国小儿急救医学, 2021, 28(2):111-115.
[22]	蒋晓慧, 王婷, 戴鸽, 等. 新冠疫情前后小儿毛细支气管炎临床特征和病原学变化[J]. 国际儿科学杂志, 2022, 49(9):629-634.
[23]	黄凤, 顾文婧, 蒋吴君, 等. 苏州地区流感嗜血杆菌感染与环境气候的相关因素分析[J]. 中国当代儿科杂志, 2022, 24(12):1351-1355.
[24]	温顺航, 林祖潘, 周必高, 等. 温州地区住院儿童下呼吸道腺病毒感染的流行特征及与气象因素的相关性[J]. 温州医科大学学报, 2021, 51(1): 25-29.
[25]	张兰豫, 庄唯, 王娇梅. 白银地区2020-2021年度呼吸道感染住院患儿病毒性病原谱发病状况分析[J]. 中国中西医结合儿科学, 2022, 14(6):486-490.
[26]	袁欣琦, 蒋凤碧, 卢瑞鸽, 等. 儿童急性肺炎支原体感染与气候变化相关性分析[J]. 中国妇幼健康研究, 2022, 33(1):24-28.

组别		例数	性别[例(%)]				年龄(月)		年龄[例(%)]						住院时间 (天)
组别		例数	男		女		年龄(月)		<12月		12~60月		>60月		住院时间 (天)
疫情前		141	80(56.74)		61(43.26)		40.29±47.97		42(29.79)		97(68.79)		2(1.42)		26.42±24.88
疫情后		127	71(55.91)		56(44.09)		54.51±58.71		38(29.92)		80(62.99)		9(7.09)		21.13±14.85
χ²/t值			0.019				2.268		0.001		1.003		4.109		2.073
P值			0.891				0.024		0.981		0.317		0.043		0.039
组别	机械通气[例(%)]					机械通气时间 (天)		基础疾病 [例(%)]		基础疾病史[例(%)]
组别	是			否		机械通气时间 (天)		基础疾病 [例(%)]		血液系统疾病		神经系统疾病		呼吸系统疾病		心血管系统疾病
疫情前	128(90.78)			13(9.22)		12.67±21.96		100(70.92)		35(24.82)		32(22.70)		21(14.89)		12(8.51)
疫情后	120(94.49)			7(5.51)		9.53±11.25		106(83.46)		44(34.65)		33(25.98)		19(14.96)		10(7.87)
χ²/F值	1.330					1.494		5.911		3.101		0.393		0.000		0.036
P值	0.249					0.137		0.015		0.078		0.530		0.988		0.850

组别		例数	性别[例(%)]				年龄(月)		年龄[例(%)]						住院时间 (天)
组别		例数	男		女		年龄(月)		<12月		12~60月		>60月		住院时间 (天)
疫情前		141	80(56.74)		61(43.26)		40.29±47.97		42(29.79)		97(68.79)		2(1.42)		26.42±24.88
疫情后		127	71(55.91)		56(44.09)		54.51±58.71		38(29.92)		80(62.99)		9(7.09)		21.13±14.85
χ²/t值			0.019				2.268		0.001		1.003		4.109		2.073
P值			0.891				0.024		0.981		0.317		0.043		0.039
组别	机械通气[例(%)]					机械通气时间 (天)		基础疾病 [例(%)]		基础疾病史[例(%)]
组别	是			否		机械通气时间 (天)		基础疾病 [例(%)]		血液系统疾病		神经系统疾病		呼吸系统疾病		心血管系统疾病
疫情前	128(90.78)			13(9.22)		12.67±21.96		100(70.92)		35(24.82)		32(22.70)		21(14.89)		12(8.51)
疫情后	120(94.49)			7(5.51)		9.53±11.25		106(83.46)		44(34.65)		33(25.98)		19(14.96)		10(7.87)
χ²/F值	1.330					1.494		5.911		3.101		0.393		0.000		0.036
P值	0.249					0.137		0.015		0.078		0.530		0.988		0.850

组别	例数	良好	不佳
疫情前	141	118(83.68)	23(16.32)
疫情后	127	112(88.19)	15(11.81)
χ²值		1.112
P值		0.292

组别	例数	良好	不佳
疫情前	141	118(83.68)	23(16.32)
疫情后	127	112(88.19)	15(11.81)
χ²值		1.112
P值		0.292

组别	例数	1~3月	4~6月	7~9月	10~12月
疫情前	141	25(17.73)	28(19.86)	27(19.15)	61(43.26)
疫情后	127	20(15.75)	30(23.62)	25(19.69)	52(40.94)
χ²值		0.188	0.588	0.012	0.147
P值		0.665	0.455	0.912	0.701